Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Koichi Azuma, Toyoaki Hida, Masataka Hirabayashi, Tetsuya Oguri, Hiroshi Tanaka, Noriyuki Ebi, Toshiyuki Sawa, Akihiro Bessho, Motoko Tachihara, Hiroaki Akamatsu, Shuji Bandoh, Daisuke Himeji, Tatsuo Ohira, Mototsugu Shimokawa, Yoichi Nakanishi, Kazuhiko Nakagawa, Kazuto Nishio

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Introduction: Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic. Methods: We developed and evaluated liquid biopsy assays for detection of TKIsensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFRTKI resistance. Results: A total of 260 patients was enrolled between November 2014 and March 2015 at 29 centers for this West Japan Oncology Group (WJOG 8014LTR) study. Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites fluid from 41 patients were collected after the development of EGFR-TKI resistance. All plasma samples were genotyped successfully and the results were reported to physicians within 14 days. TKI-sensitizing and T790M mutations were detected in plasma of 120 (46.2%) and 75 (28.8%) patients, respectively. T790M was detected in 56.7% of patients with plasma positive for TKI-sensitizing mutations. For the 41 patients with paired samples obtained after acquisition of EGFRTKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0% for TKI-sensitizing mutations and 65.9% for T790M. Conclusions: Noninvasive genotyping by ddPCR with cell-free DNA extracted from plasma is a promising approach to the detection of gene mutations during targeted treatment.

Original languageEnglish
Pages (from-to)58492-58499
Number of pages8
JournalOncotarget
Volume7
Issue number36
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Japan
Mutation
Polymerase Chain Reaction
Malignant Pleural Effusion
Biopsy
Neoplasms
Ascites
Physicians
DNA
Pharmaceutical Preparations
Genes

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). / Takahama, Takayuki; Sakai, Kazuko; Takeda, Masayuki; Azuma, Koichi; Hida, Toyoaki; Hirabayashi, Masataka; Oguri, Tetsuya; Tanaka, Hiroshi; Ebi, Noriyuki; Sawa, Toshiyuki; Bessho, Akihiro; Tachihara, Motoko; Akamatsu, Hiroaki; Bandoh, Shuji; Himeji, Daisuke; Ohira, Tatsuo; Shimokawa, Mototsugu; Nakanishi, Yoichi; Nakagawa, Kazuhiko; Nishio, Kazuto.

In: Oncotarget, Vol. 7, No. 36, 01.01.2016, p. 58492-58499.

Research output: Contribution to journalArticle

Takahama, T, Sakai, K, Takeda, M, Azuma, K, Hida, T, Hirabayashi, M, Oguri, T, Tanaka, H, Ebi, N, Sawa, T, Bessho, A, Tachihara, M, Akamatsu, H, Bandoh, S, Himeji, D, Ohira, T, Shimokawa, M, Nakanishi, Y, Nakagawa, K & Nishio, K 2016, 'Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)', Oncotarget, vol. 7, no. 36, pp. 58492-58499. https://doi.org/10.18632/oncotarget.11303
Takahama, Takayuki ; Sakai, Kazuko ; Takeda, Masayuki ; Azuma, Koichi ; Hida, Toyoaki ; Hirabayashi, Masataka ; Oguri, Tetsuya ; Tanaka, Hiroshi ; Ebi, Noriyuki ; Sawa, Toshiyuki ; Bessho, Akihiro ; Tachihara, Motoko ; Akamatsu, Hiroaki ; Bandoh, Shuji ; Himeji, Daisuke ; Ohira, Tatsuo ; Shimokawa, Mototsugu ; Nakanishi, Yoichi ; Nakagawa, Kazuhiko ; Nishio, Kazuto. / Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). In: Oncotarget. 2016 ; Vol. 7, No. 36. pp. 58492-58499.
@article{41c00e0e31b645d787e5495c73875588,
title = "Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)",
abstract = "Introduction: Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic. Methods: We developed and evaluated liquid biopsy assays for detection of TKIsensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFRTKI resistance. Results: A total of 260 patients was enrolled between November 2014 and March 2015 at 29 centers for this West Japan Oncology Group (WJOG 8014LTR) study. Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites fluid from 41 patients were collected after the development of EGFR-TKI resistance. All plasma samples were genotyped successfully and the results were reported to physicians within 14 days. TKI-sensitizing and T790M mutations were detected in plasma of 120 (46.2{\%}) and 75 (28.8{\%}) patients, respectively. T790M was detected in 56.7{\%} of patients with plasma positive for TKI-sensitizing mutations. For the 41 patients with paired samples obtained after acquisition of EGFRTKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0{\%} for TKI-sensitizing mutations and 65.9{\%} for T790M. Conclusions: Noninvasive genotyping by ddPCR with cell-free DNA extracted from plasma is a promising approach to the detection of gene mutations during targeted treatment.",
author = "Takayuki Takahama and Kazuko Sakai and Masayuki Takeda and Koichi Azuma and Toyoaki Hida and Masataka Hirabayashi and Tetsuya Oguri and Hiroshi Tanaka and Noriyuki Ebi and Toshiyuki Sawa and Akihiro Bessho and Motoko Tachihara and Hiroaki Akamatsu and Shuji Bandoh and Daisuke Himeji and Tatsuo Ohira and Mototsugu Shimokawa and Yoichi Nakanishi and Kazuhiko Nakagawa and Kazuto Nishio",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11303",
language = "English",
volume = "7",
pages = "58492--58499",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "36",

}

TY - JOUR

T1 - Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

AU - Takahama, Takayuki

AU - Sakai, Kazuko

AU - Takeda, Masayuki

AU - Azuma, Koichi

AU - Hida, Toyoaki

AU - Hirabayashi, Masataka

AU - Oguri, Tetsuya

AU - Tanaka, Hiroshi

AU - Ebi, Noriyuki

AU - Sawa, Toshiyuki

AU - Bessho, Akihiro

AU - Tachihara, Motoko

AU - Akamatsu, Hiroaki

AU - Bandoh, Shuji

AU - Himeji, Daisuke

AU - Ohira, Tatsuo

AU - Shimokawa, Mototsugu

AU - Nakanishi, Yoichi

AU - Nakagawa, Kazuhiko

AU - Nishio, Kazuto

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic. Methods: We developed and evaluated liquid biopsy assays for detection of TKIsensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFRTKI resistance. Results: A total of 260 patients was enrolled between November 2014 and March 2015 at 29 centers for this West Japan Oncology Group (WJOG 8014LTR) study. Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites fluid from 41 patients were collected after the development of EGFR-TKI resistance. All plasma samples were genotyped successfully and the results were reported to physicians within 14 days. TKI-sensitizing and T790M mutations were detected in plasma of 120 (46.2%) and 75 (28.8%) patients, respectively. T790M was detected in 56.7% of patients with plasma positive for TKI-sensitizing mutations. For the 41 patients with paired samples obtained after acquisition of EGFRTKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0% for TKI-sensitizing mutations and 65.9% for T790M. Conclusions: Noninvasive genotyping by ddPCR with cell-free DNA extracted from plasma is a promising approach to the detection of gene mutations during targeted treatment.

AB - Introduction: Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic. Methods: We developed and evaluated liquid biopsy assays for detection of TKIsensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFRTKI resistance. Results: A total of 260 patients was enrolled between November 2014 and March 2015 at 29 centers for this West Japan Oncology Group (WJOG 8014LTR) study. Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites fluid from 41 patients were collected after the development of EGFR-TKI resistance. All plasma samples were genotyped successfully and the results were reported to physicians within 14 days. TKI-sensitizing and T790M mutations were detected in plasma of 120 (46.2%) and 75 (28.8%) patients, respectively. T790M was detected in 56.7% of patients with plasma positive for TKI-sensitizing mutations. For the 41 patients with paired samples obtained after acquisition of EGFRTKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0% for TKI-sensitizing mutations and 65.9% for T790M. Conclusions: Noninvasive genotyping by ddPCR with cell-free DNA extracted from plasma is a promising approach to the detection of gene mutations during targeted treatment.

UR - http://www.scopus.com/inward/record.url?scp=84988428002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988428002&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11303

DO - 10.18632/oncotarget.11303

M3 - Article

C2 - 27542267

AN - SCOPUS:84988428002

VL - 7

SP - 58492

EP - 58499

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 36

ER -